PETALING JAYA: TMC Life Sciences Bhd’s net profit rose 2.2% to RM11.34mil for its fourth quarter ended Aug 31 from RM11.1mil in the previous corresponding period on higher margins.
During the quarter in review, the healthcare and fertility services provider posted a revenue increase of 9.9% to RM43.19mil from RM39.31mil previously, while its earnings per share (EPS) rose to 0.65 sen from 0.64 sen.
“The higher revenue was contributed by a higher patient load and higher intensity cases handled,” TMC said in its filings.
“A higher profit-before-tax margin of 25% compared to the quarter ended Aug 31, 2017 of 17% was mainly due to lower total operating expenditure during the current quarter,” it added.
TMC has proposed a final dividend of 1.83% or 0.183 sen for its financial year 2018 (FY18).
The counter shed half a sen to close at 73 sen yesterday.
For its FY18 to end-August, TMC’s net profit rose 7.8% to RM28.06mil compared with RM26.03mil in FY17, resulting in its EPS rising to 1.62 sen from 1.5 sen previously.
During the year in review, the group recorded a revenue of RM169.04mil, up 11%, and a pre-tax profit of RM33.4mil, up 23%, from the preceding year.
“The higher growth rate in pre-tax profit compared to revenue is mainly due to lower total operating expenditure driven by a higher earnings before interest, tax, depreciation and amortisation (Ebitda) margin of 23% during the current financial year compared to the Ebitda margin of 20% in 2017,” TMC said.
On its prospects for FY19, TMC said the group would continue to adopt measures to maintain growth by introducing more services, while ramping up outreach and marketing efforts to grow.
It noted that the construction work for the group’s expansion project at Thomson Hospital Kota Damansara was progressing on schedule, while the Thomson Iskandar Medical Hub in Johor Baru was in the midst of obtaining the relevant regulatory approvals and is expected to begin piling work by year-end.